Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Feedback plc (FDBK.L)
London, GB
Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio includes TexRAD, a patented software tool designed to extract and quantify textural features within radiological images. This assists research into all types of tumors and helps uncover biomarkers in medical imagery. They also offer TexRAD Lung, a specific software tool used for the clinical analysis of lung cancer within the European Union. Additionally, the company provides the Cadran image platform, a robust picture archiving and communication system (PACS) for hospitals and research institutes, capable of handling images from various imaging modalities like CT and PET scanners. Another key offering is Bleepa, a secure platform for clinical communications that facilitates the safe sharing of high-quality medical images.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -10.00% | -16.92% | -41.09% | +1.50% | -15.89% | -44.14% | -93.11% | -96.07% | -96.73% | -99.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-25.1% Q4'25: -5.5% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+0.0% Q4'25: +73.5% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-483.9% Q4'25: -436.1% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-475.4% Q4'25: -455.4% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-1,959.9% Q4'25: -1,179.3% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+115.2% Q4'25: +228.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
May 2015 actual |
May 2021 actual |
May 2022 actual |
May 2023 actual |
May 2024 actual |
May 2025 actual |
May 2026 1 Rev. Ana. 1 EPS Ana. |
May 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
382.0K
est: 436.4K (-12.5%)
|
287.4K
est: 280.0K (+2.6%)
|
588.6K
est: 590.0K (-0.2%)
|
1.02M
est: 980.0K (+4.6%)
|
1.18M
est: 1.17M (+0.7%)
|
885.6K
est: 884.0K (+0.2%)
|
810.0K
810.0K – 810.0K
-8.4% YoY
|
810.0K
810.0K – 810.0K
+0.0% YoY
|
| EBITDA |
-409.3K
est: -436.4K (+6.2%)
|
-2.01M
est: -280.0K (-618.3%)
|
-1.96M
est: -590.0K (-231.9%)
|
-2.61M
est: -980.0K (-166.6%)
|
-2.73M
est: -1.17M (-132.9%)
|
-4.19M
est: -884.0K (-373.7%)
|
-810.0K
-810.0K – -810.0K
+8.4% YoY
|
-810.0K
-810.0K – -810.0K
+0.0% YoY
|
| EBIT |
-448.1K
est: -436.4K (-2.7%)
|
-2.06M
est: -280.0K (-635.8%)
|
-2.51M
est: -590.0K (-326.0%)
|
-3.42M
est: -980.0K (-249.2%)
|
-3.69M
est: -1.17M (-214.5%)
|
-4.21M
est: -884.0K (-376.3%)
|
-810.0K
-810.0K – -810.0K
+8.4% YoY
|
-810.0K
-810.0K – -810.0K
+0.0% YoY
|
| Net Income |
-1.11M
est: -40.2K (-2,661.7%)
|
-1.62M
|
-2.12M
est: -9.18M (+76.9%)
|
-2.92M
est: -2.87M (-1.7%)
|
-3.30M
est: -8.04M (+59.0%)
|
-7.32M
est: -6.28M (-16.5%)
|
-7.10M
-7.10M – -7.10M
-13.0% YoY
|
-7.32M
-7.32M – -7.32M
-3.1% YoY
|
| SGA |
644.4K
est: 2.03M (-68.2%)
|
2.25M
est: 1.30M (+73.0%)
|
2.45M
est: 2.74M (-10.6%)
|
3.55M
est: 4.55M (-21.9%)
|
3.83M
est: 5.45M (-29.6%)
|
4.00M
est: 4.11M (-2.5%)
|
3.76M
3.76M – 3.76M
-8.4% YoY
|
3.76M
3.76M – 3.76M
+0.0% YoY
|
| EPS |
-1.17
est: 0.00 (-83,335.5%)
|
-0.31
|
-0.23
est: -0.32 (+28.1%)
|
-0.22
est: -0.10 (-120.0%)
|
-0.25
est: -0.28 (+10.7%)
|
-0.25
est: -0.22 (-14.2%)
|
-0.25
-0.25 – -0.25
-13.0% YoY
|
-0.26
-0.26 – -0.26
-3.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas James Oakley | Chief Executive Officer & Director | 228.4K | — |
| Michael Peter Hayball | Chief Technology Officer | 94.7K | male |
| Carrie Goldsworthy | Head of Marketing | — | female |
| Emma Jane Stuart | Chief Financial Officer & Director | — | female |
| Richard Dulcamara | Head of Sales | — | — |
| Stephen Brown | Chief Regulatory & Compliance Officer | — | — |
| Stephen McAteer | Chief Operating Officer | — | male |
| Antoine Saillant | Head of Product | — | — |
| Thomas Spankie | Head of Integration | — | — |
| Ben Edrich | Head of Engineering | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FDBK.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
